Adults newly diagnosed with type 2 diabetes generally don’t take to the idea of using insulin right off the bat. They’re worried about gaining weight and fear low blood sugars. They’re also concerned about whether they can manage the regimen and fear that taking insulin will lower their quality of life. Those concerns, however, might be assuaged by a study recently conducted by Ildiko Lingvay and his colleagues at the University of Texas Southwestern.
In the study, patients with newly diagnosed type 2 diabetes were randomly assigned to one of two groups: an insulin group that received insulin and metformin, or an oral group that received metformin, pioglitazone, and glyburide. Each group spent three years on the regimen.
At the end of the study, the findings for both groups were remarkably similar. Both groups had A1c’s of about 6%. Both had gained about four to seven kilograms and had experienced a similar number of hypoglycemic events. Compliance with the regimens, quality of life, and treatment satisfaction were also very similar between the groups. In fact, 100 percent of the folks in the insulin group who completed the study were willing to keep it up.
Source: Abstract, Diabetes Care